Literature DB >> 34907727

Association of FGF19, FGF21 and FGF23 with carbohydrate metabolism parameters and insulin resistance in patients with chronic kidney disease.

Malgorzata Marchelek-Mysliwiec1, Violetta Dziedziejko2, Katarzyna Dolegowka1, Andrzej Pawlik3, Krzysztof Safranow2, Joanna Stepniewska1, Magda Wisniewska1, Jolanta Malyszko4, Kazimierz Ciechanowski1.   

Abstract

Insulin resistance (IR) is characterised by increased gluconeogenesis in the liver and the resistance of peripheral receptors to insulin. Several factors, including IR, type 2 diabetes, new-onset diabetes after transplant (NODAT) and secondary parathyroidism, are related to chronic kidney disease (CKD). These factors are associated with higher mortality due to the increased risk of cardiovascular complications. Many factors have been identified as potential markers of IR in CKD. These factors include fibroblast growth factors (FGFs), a subfamily of endocrine polypeptides. In this study, we examined the association of FGF19, FGF21 and FGF23 with selected parameters related to carbohydrate metabolism and insulin resistance in non diabetic patients with predialysis CKD and in non diabetic patients after renal transplantation. The study included 108 non diabetic subjects: 40 patients with predialysis CKD, 45 patients with CKD who had undergone renal transplantation, and 23 healthy subjects (control group). In patients who had undergone renal transplantation, concentrations of FGF23 were increased compared to the control group and patients with predialysis CKD. The highest and lowest FGF19 concentrations were observed in CKD patients and in patients who had undergone kidney transplantation, respectively. This difference was statistically significant. Leptin concentrations were higher in CKD patients compared to the control group and patients who had undergone kidney transplantation. There were no statistically significant differences in adiponectin concentrations, lean body mass or fat tissue mass between the studied groups. HOMA-IR and insulin levels were significantly increased in CKD patients and in patients who had undergone renal transplantation in comparison to the control group. The results of the study suggest the involvement of FGF in carbohydrate metabolism and insulin resistance in patients with predialysis CKD, as well as a correlation with kidney function.

Entities:  

Keywords:  Body composition; Chronic kidney disease; FGF19; FGF21; FGF23; Insulin

Mesh:

Substances:

Year:  2020        PMID: 34907727     DOI: 10.32725/jab.2020.005

Source DB:  PubMed          Journal:  J Appl Biomed        ISSN: 1214-021X            Impact factor:   1.797


  37 in total

Review 1.  Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.

Authors:  Chiara Degirolamo; Carlo Sabbà; Antonio Moschetta
Journal:  Nat Rev Drug Discov       Date:  2015-11-16       Impact factor: 84.694

Review 2.  Metabolic roles of endocrine fibroblast growth factors.

Authors:  Isabel Fernandes-Freitas; Bryn M Owen
Journal:  Curr Opin Pharmacol       Date:  2015-10-24       Impact factor: 5.547

3.  Insulin resistance is associated with Fibroblast Growth Factor-23 in stage 3-5 chronic kidney disease patients.

Authors:  Jocelyn S Garland; Rachel M Holden; Robert Ross; Michael A Adams; Robert L Nolan; Wilma M Hopman; A Ross Morton
Journal:  J Diabetes Complications       Date:  2013-10-11       Impact factor: 2.852

4.  The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.

Authors:  Gregory Gaich; Jenny Y Chien; Haoda Fu; Leonard C Glass; Mark A Deeg; William L Holland; Alexei Kharitonenkov; Thomas Bumol; Holger K Schilske; David E Moller
Journal:  Cell Metab       Date:  2013-09-03       Impact factor: 27.287

5.  Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease.

Authors:  D Fliser; G Pacini; R Engelleiter; A Kautzky-Willer; R Prager; E Franek; E Ritz
Journal:  Kidney Int       Date:  1998-05       Impact factor: 10.612

6.  Leptin as a Potential Regulator of FGF21.

Authors:  Mohamed Asrih; Christelle Veyrat-Durebex; Anne-Laure Poher; Jacqueline Lyautey; Françoise Rohner-Jeanrenaud; François R Jornayvaz
Journal:  Cell Physiol Biochem       Date:  2016-03-17

Review 7.  Actions and mode of actions of FGF19 subfamily members.

Authors:  Seiji Fukumoto
Journal:  Endocr J       Date:  2007-09-14       Impact factor: 2.349

8.  Fibroblast growth factor 21 corrects obesity in mice.

Authors:  Tamer Coskun; Holly A Bina; Michael A Schneider; James D Dunbar; Charlie C Hu; Yanyun Chen; David E Moller; Alexei Kharitonenkov
Journal:  Endocrinology       Date:  2008-08-07       Impact factor: 4.736

Review 9.  Fibroblast growth factor 21 in chronic kidney disease.

Authors:  Sahapab Anuwatmatee; Shudi Tang; Ben J Wu; Kerry-Anne Rye; Kwok Leung Ong
Journal:  Clin Chim Acta       Date:  2017-11-06       Impact factor: 3.786

10.  Fibroblast growth factor-23 is a strong predictor of insulin resistance among chronic kidney disease patients.

Authors:  Ahmed Fayed; Mahmoud M El Nokeety; Ahmed A Heikal; Dina O Abdulazim; Mervat M Naguib; Usama A A Sharaf El Din
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.